Related Experiment Video

Updated: Nov 4, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

10.4K

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Si-Min Qi1, Jinyun Dong2, Zhi-Yuan Xu2

  • 1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.

Frontiers in Pharmacology
|May 24, 2021
PubMed

Insights

Proteolysis targeting chimeric (PROTAC) technology offers a novel approach to degrade target proteins for cancer treatment. Recent clinical trials show promising results for oral PROTACs in treating prostate and breast cancers.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Proteolysis targeting chimeric (PROTAC) technology is an emerging tool for endogenous protein degradation.
  • PROTACs leverage the ubiquitin-proteasome system (UPS) to target proteins for degradation, impacting tumor growth.
  • Existing literature supports the feasibility of PROTACs for targeted protein degradation.

Purpose of the Study:

  • To review the structures and mechanisms of PROTAC molecules.
  • To categorize effective PROTAC degraders based on their E3 ligase components.
  • To highlight the therapeutic potential of PROTACs in cancer treatment.

Main Methods:

  • Literature review focusing on PROTAC structures and mechanisms.
  • Analysis of PROTACs classified by their associated E3 ligases.
  • Examination of clinical trial data for oral PROTACs.

Main Results:

  • PROTAC technology demonstrates efficacy in degrading target proteins.
  • Oral PROTACs (ARV-110 and ARV-471) have shown encouraging clinical trial outcomes for prostate and breast cancers.
  • Several classes of effective PROTAC degraders utilizing different E3 ligases have been identified.

Conclusions:

  • PROTAC technology is a promising strategy for cancer therapy.
  • The development of oral PROTACs marks a significant advancement in cancer treatment accessibility.
  • Further research into PROTAC structures, mechanisms, and E3 ligase combinations will drive innovation in targeted protein degradation.
Keywords:
E3 ubiquitin ligasePROTACcancer therapyprotein degradationubiquitin-proteasome system

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.5K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.2K
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.3K
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.3K